Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 173

Similar articles for PubMed (Select 23498074)

1.

[Advances in the secondary prevention of cardioembolic stroke].

Masjuan J.

Med Clin (Barc). 2012 Oct;139 Suppl 2:51-5. doi: 10.1016/S0025-7753(12)70043-X. Review. Spanish.

PMID:
23498074
2.

Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.

Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ.

Am J Cardiol. 2012 Aug 1;110(3):453-60. doi: 10.1016/j.amjcard.2012.03.049. Epub 2012 Apr 24. Review.

PMID:
22537354
3.

Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.

Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J.

Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):480-6. doi: 10.1161/CIRCOUTCOMES.112.965988. Epub 2012 Jul 10.

4.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
5.

Novel oral anticoagulants in secondary prevention of stroke.

Diener HC, Easton JD, Hankey GJ, Hart RG.

Best Pract Res Clin Haematol. 2013 Jun;26(2):131-9. doi: 10.1016/j.beha.2013.07.007. Epub 2013 Jul 30. Review.

PMID:
23953901
6.

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.

Mantha S, Ansell J.

Thromb Haemost. 2012 Sep;108(3):476-84. doi: 10.1160/TH12-02-0093. Epub 2012 Jun 28. Review.

PMID:
22740145
7.

New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.

Aguilar MI, Kuo RS, Freeman WD.

Neurol Clin. 2013 Aug;31(3):659-75. doi: 10.1016/j.ncl.2013.03.001. Review.

PMID:
23896498
8.

Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.

Harrington AR, Armstrong EP, Nolan PE Jr, Malone DC.

Stroke. 2013 Jun;44(6):1676-81. doi: 10.1161/STROKEAHA.111.000402. Epub 2013 Apr 2.

9.

Novel anticoagulants eliminate the need for left atrial appendage exclusion devices.

Ezekowitz MD, Kent AP.

Circulation. 2014 Oct 21;130(17):1505-14. doi: 10.1161/CIRCULATIONAHA.114.008139. No abstract available.

PMID:
25332278
10.

Novel oral anticoagulants in non-valvular atrial fibrillation.

Potpara TS, Lip GY.

Best Pract Res Clin Haematol. 2013 Jun;26(2):115-29. doi: 10.1016/j.beha.2013.07.008. Epub 2013 Jul 21. Review.

PMID:
23953900
11.

Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.

Lip GY, Larsen TB, Skjøth F, Rasmussen LH.

J Am Coll Cardiol. 2012 Aug 21;60(8):738-46. doi: 10.1016/j.jacc.2012.03.019. Epub 2012 May 9.

12.

Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.

Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.

Int Angiol. 2012 Aug;31(4):330-9. Review.

PMID:
22801398
13.

New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.

Tran H, Joseph J, Young L, McRae S, Curnow J, Nandurkar H, Wood P, McLintock C.

Intern Med J. 2014 Jun;44(6):525-36. doi: 10.1111/imj.12448.

PMID:
24946813
14.

Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.

Contractor T, Levin V, Martinez MW, Marchlinski FE.

Postgrad Med. 2013 Jan;125(1):34-44. doi: 10.3810/pgm.2013.01.2622. Review.

PMID:
23391669
15.

Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.

Berman JP, Halperin JL.

Hosp Pract (1995). 2013 Feb;41(1):37-48. doi: 10.3810/hp.2013.02.1006. Review.

PMID:
23466966
16.

Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.

Rognoni C, Marchetti M, Quaglini S, Liberato NL.

Clin Drug Investig. 2014 Jan;34(1):9-17. doi: 10.1007/s40261-013-0144-3.

PMID:
24135964
17.

Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.

Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J.

J Med Econ. 2013 Sep;16(9):1163-8. doi: 10.3111/13696998.2013.826664. Epub 2013 Aug 8.

PMID:
23869941
18.

[Improvements in oral anticoagulant therapy for atrial fibrillation].

Briongos Figuero S, García Santos-Gallego C, Badimón JJ.

Med Clin (Barc). 2013 Dec 7;141(11):487-93. doi: 10.1016/j.medcli.2013.02.015. Epub 2013 Apr 16. Review. Spanish.

PMID:
23597953
19.

New alternative anticoagulants in atrial fibrillation: the move beyond warfarin.

Bhimani AA, Hong M.

Rev Recent Clin Trials. 2013 Jun;8(2):78-85. Review.

PMID:
23859143
20.

Concerns about studies investigating new anticoagulant drugs for stroke prevention in atrial fibrillation.

Stöllberger C, Finsterer J.

J Neurol. 2012 Jan;259(1):168-9. doi: 10.1007/s00415-011-6328-y. Epub 2011 Nov 29. No abstract available.

PMID:
22124666
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk